Sökning: WFRF:(Beisland Christian) > Local treatment of ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06029naa a2200673 4500 | |
001 | oai:DiVA.org:umu-202681 | |
003 | SwePub | |
008 | 230112s2023 | |||||||||||000 ||eng| | |
009 | oai:lup.lub.lu.se:29b0e1c5-b64e-4d06-b230-b884030b2c6e | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-2026812 URI |
024 | 7 | a https://doi.org/10.1016/j.euros.2022.11.0082 DOI |
024 | 7 | a https://lup.lub.lu.se/record/29b0e1c5-b64e-4d06-b230-b884030b2c6e2 URI |
040 | a (SwePub)umud (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Marconi, Lorenzou University Hospital of Coimbra4 aut |
245 | 1 0 | a Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups |
264 | 1 | b Elsevier,c 2023 |
338 | a electronic2 rdacarrier | |
520 | a BACKGROUND: Retrospective comparative studies suggest a survival benefit after complete local treatment of recurrence (LTR) in renal cell carcinoma (RCC), which may be largely due to an indication bias.OBJECTIVE: To determine the role of LTR in a homogeneous population characterised by limited and potentially resectable recurrence.DESIGN SETTING AND PARTICIPANTS: RECUR is a protocol-based multicentre European registry capturing patient and tumour characteristics, risk of recurrence (RoR), recurrence patterns, and survival of those curatively treated for nonmetastatic RCC from 2006 to 2011. Per-protocol resectable disease (RD) recurrence was defined as (1) solitary metastases, (2) oligometastases, or (3) renal fossa or renal recurrence after radical or partial nephrectomy, respectively.INTERVENTION: Local treatment of recurrence.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) and cancer-specific survival was compared in the RD population that underwent LTR versus no LTR. We constructed a multivariate model to predict risk factors for overall mortality and analysed the effect of LTR across RoR groups.RESULTS AND LIMITATIONS: Of 3039 patients with localised RCC treated with curative intent, 505 presented with recurrence, including 176 with RD. Of these patients, 97 underwent LTR and 79 no LTR. Patients in the LTR group were younger (64.3 [40-80] vs 69.2 [45-87] yr; p = 0.001). The median OS was 70.3 mo (95% confidence interval [CI] 58-82.6) versus 27.4 mo (95% CI 23.6-31.15) in the LTR versus no-LTR group (p < 0.001). After a multivariate analysis, having LTR (hazard ratio [HR] 0.37 [95% CI 0.2-0.6]), having low- versus high-risk RoR (HR 0.42 [95% CI [0.20-0.83]), and not having extra-abdominal/thoracic metastasis (HR 1.96 [95% CI 1.02-3.77]) were prognostic factors of longer OS. The LTR effect on survival was consistent across risk groups. OS HR for high, intermediate, and low risks were 0.36 (0.2-0.64), 0.27 (0.11-0.65), and 0.26 (0.08-0.8), respectively. Limitations include retrospective design.CONCLUSIONS: This is the first study assessing the effectiveness of LTR in RCC in a comparable population with RD. This study supports the role of LTR across all RoR groups.PATIENT SUMMARY: We assessed the effectiveness of local treatment of resectable recurrent renal cell carcinoma after surgical treatment of the primary kidney tumour. Local treatment of recurrence was associated with longer survival across groups with a risk of recurrence. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Metastasectomy | |
653 | a Metastatic | |
653 | a Radiotherapy | |
653 | a Renal cell cancer | |
653 | a Stereotactic body radiotherapy | |
653 | a Surgery | |
653 | a Systemic therapy | |
653 | a Metastasectomy | |
653 | a Metastatic | |
653 | a Radiotherapy | |
653 | a Renal cell cancer | |
653 | a Stereotactic body radiotherapy | |
653 | a Surgery | |
653 | a Systemic therapy | |
700 | 1 | a Kuusk, Teeleu Royal London Hospital4 aut |
700 | 1 | a Capitanio, Umbertou San Raffaele Hospital4 aut |
700 | 1 | a Beisland, Christianu Haukeland University Hospital,University of Bergen4 aut |
700 | 1 | a Lam, Thomasu University of Aberdeen4 aut |
700 | 1 | a Pello, Sergio Fernandezu University Hospital Cabueñes4 aut |
700 | 1 | a Stewart, Grant Du Cambridge University Hospitals NHS Foundation Trust,University of Cambridge4 aut |
700 | 1 | a Klatte, Tobiasu Charité - University Medicine Berlin4 aut |
700 | 1 | a Volpe, Alessandrou University of Eastern Piedmont4 aut |
700 | 1 | a Ljungberg, Börje,c Professor,d 1949-u Umeå University,Umeå universitet,Urologi och andrologi4 aut0 (Swepub:umu)bolj0001 |
700 | 1 | a Dabestani, Saeedu Lund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,Urologi,Urological cancer, Malmö,Lund University Research Groups,Urology4 aut0 (Swepub:lu)med-sdd |
700 | 1 | a Bex, Axelu Antoni Van Leeuwenhoek Hospital,University College London4 aut |
710 | 2 | a University Hospital of Coimbrab Royal London Hospital4 org |
773 | 0 | t European Urology Open Scienced : Elsevierg 47, s. 65-72q 47<65-72x 2666-1691x 2666-1683 |
856 | 4 | u https://doi.org/10.1016/j.euros.2022.11.008y Fulltext |
856 | 4 | u https://umu.diva-portal.org/smash/get/diva2:1726191/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u http://dx.doi.org/10.1016/j.euros.2022.11.008x freey FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-202681 |
856 | 4 8 | u https://doi.org/10.1016/j.euros.2022.11.008 |
856 | 4 8 | u https://lup.lub.lu.se/record/29b0e1c5-b64e-4d06-b230-b884030b2c6e |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy